EMERGENT BIOSOLUTIONS INC. Form 8-K (Jan. 13, 2022)

Summary

A Form 8-K current report of Emergent BioSolutions Inc. for January 13, 2022, signed by Richard S. Lindahl, Executive Vice President, Chief Financial Officer and Treasurer, on a line dated January 14, 2022. Under Item 5.02 Fuad El-Hibri, Founder and Executive Chairman of the Board of Directors, notified the company on January 13, 2022 of his retirement and resignation as an officer, director and employee, effective April 1, 2022. The filing states that the retirement is not the result of any dispute or disagreement with the company, its management or the Board, and that Fuad El-Hibri is expected to be available afterward on an advisory and consulting basis. Item 7.01 furnishes a January 14, 2022 press release as Exhibit 99.1.

Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used

Full text

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 13, 2022

EMERGENT BIOSOLUTIONS INC.

(Exact name of registrant as specified in its charter)

Delaware | 001-33137 | 14-1902018
(State or other jurisdiction | (Commission File Number) | (IRS Employer
of incorporation) | Identification No.)

400 Professional Drive , Suite 400 ,

Gaithersburg , Maryland 20879

(Address of principal executive offices, including zip code)

( 240 ) 631-3200

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class | Trading Symbol(s) | Name of each exchange on which registered
Common Stock, Par Value $0.001 per share | EBS | New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On January 13, 2022, Fuad El-Hibri, Founder and Executive Chairman of the Board of Directors (the “Board”) of Emergent BioSolutions Inc. (the “Company”), notified the Company of his retirement and resignation as an officer, director and employee of the Company, effective as of April 1, 2022. Mr. El-Hibri informed the Company that his retirement is not the result of any dispute or disagreement with the Company, its management or the Board. It is expected that Mr. El-Hibri will be available following his retirement as needed on an advisory and consulting basis on terms to be agreed by the Company and Mr. El-Hibri.

Item 7.01. Regulation FD Disclosure.

On January 14, 2022, the Company issued a press release regarding Mr. El-Hibri’s retirement, a copy of which is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No. | Description
99.1 | Press release issued on January 14 , 2022.
101 | Emergent BioSolutions Inc. Current Report on Form 8-K, dated January 13, 2022 formatted in XBRL (Extensible Business Reporting Language): Cover Page. The instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
104 | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

EMERGENT BIOSOLUTIONS INC.
Dated: January 14, 2022 | By: | /s/ RICHARD S. LINDAHL
Name: Richard S. Lindahl Title: Executive Vice President, Chief Financial Officer and Treasurer

File and source

File

SEC_EBS_8-K_filed2022-01-14_0001367644-22-000006.htm

Size

36,263 bytes

SHA-256

69f8cfc3241b00a1c5790c37c4e70df4e2d5dd0f0fb80582545f1fc29b2c71c3

Our copy

SEC_EBS_8-K_filed2022-01-14_0001367644-22-000006.htm

Original

www.sec.gov